T. Rowe Price Investment Management, Inc. Veracyte, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Veracyte, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 360 shares of VCYT stock, worth $12,960. This represents 0.0% of its overall portfolio holdings.
Number of Shares
360Holding current value
$12,960% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VCYT
# of Institutions
295Shares Held
77.2MCall Options Held
0Put Options Held
17.6K-
Vanguard Group Inc Valley Forge, PA8.1MShares$292 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.79MShares$281 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI5.24MShares$189 Million0.27% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl3.8MShares$137 Million0.85% of portfolio
-
Wellington Management Group LLP Boston, MA3.47MShares$125 Million0.02% of portfolio
About VERACYTE, INC.
- Ticker VCYT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,575,904
- Market Cap $2.58B
- Description
- Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...